Benzoxazole kinase inhibitors and methods of use

1. A process for synthesizing a compound of Formula C:

comprising the step of allowing a compound of Formula A to react with a compound of Formula B under conditions that are effective for synthesizing a compound of Formula C; wherein:

T 1 is halo;

X 1 is N, X 2 is N, and X 3 is C;

R 1 is hydrogen, -L-C 1-10 alkyl, -L-C 3-8 cycloalkyl, -L-C 1-10 alkylheterocyclyl, or -L-heterocyclyl, each of which is unsubstituted or is substituted by one or more independent R 3 ;

L is a bond, —(C═O)—, —C(═O)O—, —C(═O)N(R 31 )—, —S—, —S(O)—, —S(O) 2 —, —S(O) 2 N(R 31 )—, or —N(R 31 )—;

each of G is independently H or R G1 ; and R G1 is alkyl, alkenyl, or aryl;

or the G groups of

join together to form a 5- or 6-membered cyclic moiety;

M of Formula B is a M 1 moiety, and wherein the M moiety of Formula B and the M 1 moiety of Formula C are identical, having the structure:

k is 1;

W 2 is —O—, —NR 7 —, —S(O) 0-2 —, —C(O)—, —C(O)N(R 7 )—, —N(R 7 )C(O)—, —N(R 7 )C(O)N(R 8 )—, —N(R 7 )S(O)—, —N(R 7 )S(O) 2 —, —C(O)O—, —CH(R 7 )N(C(O)OR 8 )—, —CH(R 7 )N(C(O)R 8 )—, —CH(R 7 )N(SO 2 R 8 )—, —CH(R 7 )N(R 8 )—, —CH(R 7 )C(O)N(R 8 )—, —CH(R 7 )N(R 8 )C(O)—, —CH(R 7 )N(R 8 )S(O)—, or —CH(R 7 )N(R 8 )S(O) 2 —;

R 2 is hydrogen, halogen, —OH, —R 31 , —CF 3 , —OCF 3 , —OR 31 , —NR 31 R 32 , —NR 34 R 35 , —C(O)R 31 , —CO 2 R 31 , —C(═O)NR 31 R 32 , —C(═O)NR 34 R 35 , —NO 2 , —CN, —S(O) 0-2 R 31 , —SO 2 NR 31 R 32 , —SO 2 NR 34 R 35 , —NR 31 C(═O)R 32 , —NR 31 C(═O)OR 32 , —NR 31 C(═O)NR 32 R 33 , —NR 31 S(O) 0-2 R 32 , —C(═S)OR 31 , —C(═O)SR 31 , —NR 31 C(═NR 32 )NR 33 R 32 , —NR 31 C(═NR 32 )OR 33 , —NR 31 C(═NR 32 )SR 33 , —OC(═O)OR 33 , —OC(═O)NR 31 R 32 , —OC(═O)SR 31 , —SC(═O)OR 31 , —P(O)OR 31 OR 32 , —SC(═O)NR 31 R 32 , bicyclic aryl, substituted monocyclic aryl, hetaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 1-10 alkyl-C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, C 3-8 cycloalkyl-C 2-10 alkenyl, C 3-8 cycloalkyl-C 2-10 alkynyl, C 1-10 alkyl-C 2-10 alkenyl, C 1-10 alkyl-C 2-10 alkynyl, C 2-10 alkyl-monocyclic aryl, monocyclic aryl-C 2-10 alkyl, C 1-10 alkylbicycloaryl, bicycloaryl-C 1-10 alkyl, substituted C 1-10 alkylaryl, substituted aryl-C 1-10 alkyl, C 1-10 alkylhetaryl, C 1-10 alkylheterocyclyl, C 2-10 alkenyl, C 2-10 alkynyl, C 2-10 alkenyl-C 1-10 alkyl, C 2-10 alkynyl-C 1-10 alkyl, C 2-10 alkenylaryl, C 2-10 alkenylhetaryl, C 2-10 alkenylheteroalkyl, C 2-10 alkenylheterocyclyl, C 2-10 alkenyl-C 3-8 cycloalkyl, C 2-10 alkynylaryl, C 2-10 alkynylhetaryl, C 2-10 alkynylheteroalkyl, C 2-10 alkynylheterocylyl, C 2-10 alkynyl-C 3-8 cycloalkenyl, C 1-10 alkoxy C 1-10 alkyl, C 1-10 alkoxyC 2-10 alkenyl, C 1-10 alkoxyC 2-10 alkynyl, heterocyclyl, heteroalkyl, heterocyclyl-C 1-10 alkyl, heterocyclyl-C 2-10 alkenyl, heterocyclyl-C 2-10 alkynyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, aryl-heterocyclyl, hetaryl-C 1-10 alkyl, hetaryl-C 2-10 alkenyl, hetaryl-C 2-10 alkynyl, hetaryl-C 3-8 cycloalkyl, hetaryl-heteroalkyl, or hetaryl-heterocyclyl, wherein each of said bicyclic aryl or heteroaryl moiety is unsubstituted, or wherein each of bicyclic aryl, heteroaryl moiety or monocyclic aryl moiety is substituted with one or more independent halo, —OH, —R 31 , —CF 3 , —OCF 3 , —OR 31 , —NR 31 R 32 , —NR 34 R 35 , —C(O)R 31 , —CO 2 R 31 , —C(═O)NR 31 R 32 , —C(═O)NR 34 R 35 , —NO 2 , —CN, —S(O) 0-2 R 31 , —SO 2 NR 31 R 32 , —SO 2 NR 34 R 35 , —NR 31 C(═O)R 32 , —NR 31 C(═O)OR 32 , —NR 31 C(═O)NR 32 R 33 , —NR 31 S(O) 0-2 R 32 , —C(═S)OR 31 , —C(═O)SR 31 , —NR 31 C(═NR 32 )NR 33 R 32 , —NR 31 C(═NR 32 )OR 33 , —NR 31 C(═NR 32 )SR 33 , —OC(═O)OR 33 , —OC(═O)NR 31 R 32 , —OC(═O)SR 31 , —SC(═O)OR 31 , —P(O)OR 31 OR 32 , or —SC(═O)NR 31 R 32 , and wherein each of said alkyl, cycloalkyl, heterocyclyl, or heteroalkyl moiety is unsubstituted or is substituted with one or more halo, —OH, —R 31 , —CF 3 , —OCF 3 , —OR 31 , —O-aryl, —NR 31 R 32 , —NR 34 R 35 , —C(O)R 31 , —CO 2 R 31 , —C(═O)NR 34 R 35 , or —C(═O)NR 31 R 32 ;

R 3 is hydrogen, halogen, —OH, —R 31 , —CF 3 , —OCF 3 , —OR 31 , —NR 31 R 32 , —NR 34 R 35 , —C(O)R 31 , or —CO 2 R 31

R 5 is hydrogen;

each of R 31 , R 32 , and R 33 is independently H or unsubstituted C 1-10 alkyl;

R 34 and R 35 in —NR 34 R 35 , —C(═O)NR 34 R 35 , or —SO 2 NR 34 R 35 , are taken together with the nitrogen atom to which they are attached to form a 3-10 membered saturated or unsaturated ring; wherein said ring is independently unsubstituted or is substituted by one or more —NR 31 R 32 , hydroxyl, halogen, oxo, aryl, hetaryl, C 1-6 alkyl, or O-aryl, and wherein said 3-10 membered saturated or unsaturated ring independently contains 0, 1, or 2 more heteroatoms in addition to the nitrogen atom;

each of R 7 and R 8 is independently hydrogen or C 1-10 alkyl; and

R 1 of Formula A and R 1 of Formula C are the same; R 31 of Formula A and R 31 of Formula C are the same; and R 32 of Formula A and R 32 of Formula C are the same.

2. The process of claim 1 wherein T 1 is iodo or bromo.

3. The process of claim 1 wherein:

R 1 is -L-C 1-10 alkyl, -L-C 3-8 cycloalkyl, -L-C 1-10 alkylheterocylyl, or -L-heterocyclyl, each of which is unsubstituted or is substituted by one or more independent R 3 substituents; and wherein —(W 2 )— is —NR 7 —, —N(R 7 )C(O)— or —N(R 7 )S(O) 2 —.

4. The process of claim 1 wherein the compound of Formula A reacts with the compound of Formula B in the presence of palladium tetrakis (triphenylphosphine).

5. The process of claim 1 wherein the palladium tetrakis (triphenylphosphine) is present in an amount from about 0.07 molar equivalents to about 0.15 molar equivalents of the compound of Formula A.

6. The process of claim 1 , wherein W 2 is NH, k is 1, and R 2 is H.

7. The process of claim 1 , wherein each G is H.

8. The process of claim 1 , wherein R 31 and R 32 are H.

9. The process of claim 1 , wherein T 1 is Br.

10. The process of claim 1 , wherein R 1 is isopropyl.